REHOVOT, Israel, and BRIDGEWATER, New Jersey, Feb. 6, 2017 /PRNewswire/ -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), ("Foamix"), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, announced today that Dr. Dov Tamarkin, CEO, will provide a corporate overview and business update at the BIO-CEO & Investor Conference, being held on February 13-14, 2017 at the Waldorf Astoria in New York City.
BIO CEO & Investor Conference Presentation Details
Date: Tuesday, February 14
Time: 2:00 pm Eastern Time
Location: The Waldorf Astoria, New York, New York
About Foamix Pharmaceuticals Ltd.
Foamix is a specialty pharmaceutical company focused on the development and commercialization of proprietary, innovative and differentiated topical drugs for dermatological therapy.
Our clinical stage product candidates include FMX101, our novel minocycline foam for the treatment of moderate-to-severe acne, FMX103 for the treatment of moderate-to-severe rosacea, FMX102 for the treatment of impetigo, and FDX104, our doxycycline foam for the management of acne-like rash induced by EGFRI anticancer drugs.
In addition, we have development and license agreements relating to our technology with various pharmaceutical companies including Bayer HealthCare and others.
For more information, please visit www.foamixpharma.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/foamix-pharmaceuticals-to-present-at-the-2017-bio-ceo--investor-conference-300402394.html
SOURCE Foamix Pharmaceuticals Ltd.